RCEL Avita Medical, Inc. - Common Stock
Acerca de Avita Medical, Inc. - Common Stock Descripción general de la empresa de Wikipedia
Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa (EMEA) and Australia.
Leer más
Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa (EMEA) and Australia.
Company history
Originally named "Clinical Cell Culture" and listed on the ASX under the symbol "C3", the company restructured under the name "Avita Medical" in June 2008. In 2015, the company conducted a strategic divestment of its respiratory business, including the Breath-a-Tech and Funhaler products, to support focus on its regenerative products.
Avita Medical is traded both on the Australian stock market under the ticker symbol AVH and on the American OTC stock market under the ticker symbol AVMXY.
ReCell, spray-on skin
ReCell is a device that enables clinicians to treat wounds and skin defects using very small samples of the patient's own cells. The procedure is performed on site at bedside and takes approximately 25 minutes to complete and does not require laboratory facilities, off-site culture of tissues or specialized staff. ReCell is approved in EMEA countries, China, and Australia and is in Pivotal/PIII trials in the US for burns as a first indication and a Pilot/PII US study underway for scars.
February 12, 2018 AVITA Medical announced that the U.S. Food and Drug Administration (FDA) has approved a significant increase in the number of patients who may be treated in the United States with the ReCell Autologous Cell Harvesting Device under a FDA Compassionate Use Investigational Device Exemption (IDE) program. Under the expanded protocol, up to 88 patients with life-threatening injuries, including severe burns, may be treated with ReCell. This is the fifth expansion to the Compassionate Use protocol for ReCell approved by the FDA and expands by 20 the number of patients who may be treated. Eligible patients are those who have insufficient healthy skin available for standard skin grafting treatment of their injuries and whose treating physicians believe there to be no suitable alternative treatment.
In October 2017, Avita Medical started to raise a goal of $17 million in capital for the product. The company worked with the Biomedical Advanced Research and Development Authority (BARDA) to raise money toward commercializing the product on the U.S. market.
September 28, 2017 Avita Medical announced submission of U.S. FDA Premarket Approval (PMA) Application for the ReCell device for treatment of burn injuries. The PMA submission includes clinical data from the two U.S. randomized, controlled trials with combined enrollment of 131 patients at twelve leading burn centers across the United States. The later trial demonstrated over 30% reduction in donor skin harvesting while achieving comparable near-term healing and long-term scar outcomes for treatment of third-degree burn injuries. Results from the earlier trial demonstrate a 97.5% reduction in donor skin harvested for treatment of second-degree burn injuries. The submission also includes a review of 55 cases of compassionate use of ReCell for extensive burn injuries.
September 21, 2017 Avita Medical announced the execution of an expanded contract option valued at approximately US$24.3 million. This newly executed contract option establishes funding for key clinical and health economics research in U.S. pediatric burn care and extends Avita's Project Bioshield contract through to September 2022. Avita Medical has had a strong relationship with BARDA since the execution of a five-year contract in September 2015. Under the base contract BARDA made an initial investment of US$16.9 million to support Avita's ongoing U.S. clinical regulatory program towards FDA Premarket Approval (PMA), and to procure 5,000-plus ReCell devices. The contract also allowed BARDA to exercise future options to support additional clinical trials, and provide surge capacity for up to another 20,000 ReCell devices. Supplemental funding worth up to US$7.96 million was also provided to Avita under the contract in June 2016, to provide further operational support to Avita's PMA preparation and Compassionate Use program.
On September 20, 2018, Avita Medical's ReCell wound care device received FDA PMA approval.
US Government grant
In 2009 the United States Armed Forces Institute of Regenerative Medicine provided Avita with a US$1.45 million grant to hasten the approval of the ReCell kit with the U.S. Food and Drug Administration.
Necrotizing fasciitis
In 2018 a burn center in Phoenix, Arizona held a press conference to discuss the ongoing results of using ReCell to treat a woman with flesh-eating bacteria also known as necrotizing fasciitis.
== References ==
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
RCEL Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
RCEL Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
RCEL Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
- Compra fuerte 2 20,0%
- Compra 5 50,0%
- Mantener 3 30,0%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
3 analistas · 2026-08-13Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $-0.25 | $-0.29 | 0.04% |
| 31 de marzo de 2026 | $-0.35 | $-0.29 | -0.06% |
| 31 de diciembre de 2025 | $-0.38 | $-0.34 | -0.04% |
| 30 de septiembre de 2025 | $-0.46 | $-0.29 | -0.17% |
| 30 de junio de 2025 | $-0.38 | $-0.25 | -0.13% |
| 31 de marzo de 2025 | $-0.53 | $-0.39 | -0.14% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| RCEL | $105M | -2.0 | 11.5% | -67.8% | 328.9% | 82.1% |
| CNXU | — | — | — | — | — | — |
| GLSI | $300M | -14.7 | — | — | -2159.7% | — |
| PYXS | $72M | -0.9 | -14.2% | -574.5% | -112.9% | — |
| TARA | $286M | -4.0 | — | — | -33.7% | — |
| AKBA | $427M | -80.5 | 47.5% | -2.3% | -17.3% | — |
| ALEC | $172M | -1.1 | -79.1% | -679.2% | -280.7% | — |
| EBS | $644M | 13.3 | -28.8% | 7.1% | 9.9% | — |
| ARCT | $174M | -2.6 | -46.1% | -80.2% | -29.6% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 17
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72M | $64M | $50M | $34M | · | $14M | $5M | |
| Cost of Revenue | $13M | $9M | $8M | $6M | · | $3M | $1M | |
| Gross Profit | $59M | $55M | $42M | $28M | · | $11M | $4M | |
| R&D Expense | $21M | $20M | $21M | $14M | · | $9M | $8M | |
| SG&A Expense | $27M | $33M | $28M | $23M | · | $33M | $15M | |
| Operating Expenses | $101M | $112M | $86M | $59M | · | $58M | $36M | |
| Operating Income | $-43M | $-57M | $-43M | $-28M | · | $-43M | $-26M | |
| Interest Expense | $5M | $5M | $1M | $16.0K | · | $33.0K | $27.0K | |
| Other Non-op | $-1M | $163.0K | $8M | $892.0K | · | · | · | |
| Pretax Income | $-49M | $-62M | $-35M | $-27M | · | $-42M | $-25M | |
| Income Tax | $11.0K | $54.0K | $66.0K | $36.0K | · | $4.0K | $-121.0K | |
| Net Income | $-49M | $-62M | $-35M | $-27M | · | $-42M | $-25M | |
| EPS (Basic) | $-1.74 | $-2.39 | $-1.40 | $1.07 | · | $2.07 | $1.56 | |
| EPS (Diluted) | $-1.74 | $-2.39 | $-1.40 | $1.07 | · | $2.07 | $1.56 | |
| Shares (Basic) | 27,860,784 | 25,883,056 | 25,331,264 | 25,000,180 | · | 20,290,966 | 16,064,588 | |
| Shares (Diluted) | 27,860,784 | 25,883,056 | 25,331,264 | 25,000,180 | · | 20,290,966 | 16,064,588 | |
| EBITDA | $-40M | $-55M | $-42M | $-27M | · | · | · |
Balance general 26
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10M | $14M | $22M | $18M | $56M | $74M | $20M | |
| Short-term Investments | $8M | $22M | $67M | $61M | $30M | · | · | |
| Receivables | $9M | $12M | $8M | $4M | $3M | $2M | $1M | |
| Inventory | $7M | $7M | $6M | $2M | $2M | $1M | $742.0K | |
| Prepaid Expense | $1M | $2M | $2M | $2M | $1M | $990.0K | $1M | |
| Other Current Assets | · | · | $18.0K | $127.0K | $15.0K | $75.0K | $125.0K | |
| Current Assets | $35M | $57M | $104M | $87M | $92M | $78M | $24M | |
| PP&E (Net) | $9M | $10M | $2M | $1M | $1M | $1M | $1M | |
| Accum. Depreciation | $5M | $3M | $2M | $2M | $2M | $881.0K | $667.0K | |
| Intangibles | $6M | $6M | $487.0K | $465.0K | $443.0K | $364.0K | $225.0K | |
| Other Non-current Assets | $612.0K | $546.0K | $355.0K | $122.0K | $638.0K | $1.0K | $125.0K | |
| Total Assets | $56M | $80M | $112M | $98M | $116M | $82M | $26M | |
| Accounts Payable | $9M | $6M | $4M | $3M | $3M | $4M | $2M | |
| Current Liabilities | $63M | $20M | $13M | $11M | $9M | $8M | $4M | |
| Capital Leases | $2M | $3M | $2M | $306.0K | $918.0K | $2M | · | |
| Other Non-current Liabilities | · | · | · | · | $113.0K | $0 | $42.0K | |
| Total Liabilities | $73M | $75M | $62M | $13M | $11M | $10M | $5M | |
| Long-term Debt | $43M | $42M | · | · | · | · | · | |
| Total Debt | $43M | $42M | $40M | · | · | · | · | |
| Common Stock | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | |
| Paid-in Capital | $394M | $368M | $350M | $340M | $332M | $259M | $165M | |
| Retained Earnings | $-408M | $-360M | $-298M | $-263M | $-236M | $-195M | $-153M | |
| AOCI | $-1M | $-2M | $-2M | $8M | $8M | $8M | $8M | |
| Stockholders' Equity | $-17M | $4M | $49M | $85M | $105M | $72M | $21M | |
| Liabilities + Equity | $56M | $80M | $112M | $98M | $116M | $82M | $26M | |
| Shares Outstanding | 30,571,662 | 26,354,042 | 25,682,078 | 25,208,436 | 24,925,743 | 21,467,912 | 18,712,996 |
Flujo de Efectivo 16
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $1M | $632.0K | $568.0K | · | $465.0K | $269.0K | |
| Stock-based Comp | $10M | $13M | $8M | $7M | · | $16M | $2M | |
| Amort. of Intangibles | $600.0K | $93.0K | $35.0K | $58.0K | · | $119.0K | $0 | |
| Other Non-cash | $6M | $-2M | $-12M | $9.0K | · | · | · | |
| Operating Cash Flow | $-31M | $-49M | $-38M | $-19M | · | $-23M | $-19M | |
| CapEx | $1M | $9M | $1M | $452.0K | · | $590.0K | $1M | |
| Investing Cash Flow | $12M | $37M | $2M | $-19M | · | $-847.0K | $-1M | |
| Debt Issued | · | · | $39M | · | · | · | · | |
| Net Debt Issued | · | · | $39M | · | · | · | · | |
| Stock Issued | $15M | · | · | · | · | $82M | $32M | |
| Net Stock Activity | $15M | · | · | · | · | · | · | |
| Financing Cash Flow | $15M | $4M | $40M | $900.0K | · | $77M | $30M | |
| Net Change in Cash | $-4M | $-8M | $4M | $-38M | · | $53M | $9M | |
| Taxes Paid | $15.0K | $41.0K | $44.0K | $17.0K | · | · | · | |
| Free Cash Flow | $-32M | $-58M | $-39M | $-20M | · | · | · | |
| Levered FCF | $-37M | $-63M | $-41M | $-20M | · | · | · |
Rentabilidad 8
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.1% | 85.9% | 84.5% | 82.5% | · | · | · | |
| Operating Margin | -59.4% | -88.1% | -85.1% | -79.9% | · | · | · | |
| Net Margin | -67.8% | -96.3% | -70.6% | -77.5% | · | · | · | |
| Pretax Margin | -67.8% | -96.2% | -70.4% | -77.4% | · | · | · | |
| EBITDA Margin | -56.1% | -86.3% | -83.8% | -78.3% | · | · | · | |
| ROA | -71.4% | -64.6% | -33.7% | -24.9% | · | · | · | |
| ROE | 328.9% | -739.5% | -63.2% | -30.9% | · | · | · | |
| ROIC | -161.5% | -121.2% | -48.1% | -32.5% | · | · | · |
Liquidez y Solvencia 5
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.6 | 2.8 | 7.9 | 8.2 | · | · | · | |
| Quick Ratio | 0.4 | 2.4 | 7.3 | 7.7 | · | · | · | |
| Debt / Equity | -2.6 | 9.4 | 0.8 | · | · | · | · | |
| LT Debt / Equity | 0.0 | 9.4 | 0.8 | · | · | · | · | |
| Interest Coverage | -8.5 | -10.6 | -37.3 | -1719.1 | · | · | · |
Eficiencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.1 | 0.7 | 0.5 | 0.3 | · | · | · | |
| Inventory Turnover | 1.8 | 1.4 | 2.0 | 2.8 | · | · | · | |
| Receivables Turnover | 6.9 | 6.6 | 9.0 | 10.4 | · | · | · |
Tasas de Crecimiento 2
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.5% | 28.1% | 45.7% | · | · | · | · | |
| Revenue CAGR 3Y | 27.7% | · | · | · | · | · | · |
Valoración (TTM) 14
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $72M | $64M | $50M | $34M | · | $14M | · | |
| Net Income TTM | $-49M | $-62M | $-35M | $-27M | · | $-42M | · | |
| Market Cap | $105M | $337M | $352M | $166M | · | · | · | |
| Enterprise Value | $130M | $344M | $303M | · | · | · | · | |
| P/E | -2.0 | -5.4 | -9.8 | 6.2 | · | 14.8 | · | |
| P/S | 1.5 | 5.3 | 7.0 | 4.8 | · | · | · | |
| P/B | -6.3 | 75.0 | 7.2 | 2.0 | · | · | · | |
| P / Tangible Book | · | · | 7.3 | 2.0 | · | 9.1 | · | |
| P / Cash Flow | -3.4 | -6.9 | -9.3 | -8.7 | · | · | · | |
| P / FCF | -3.3 | -5.8 | -8.9 | -8.5 | · | · | · | |
| EV / EBITDA | -3.2 | -6.2 | -7.2 | · | · | · | · | |
| EV / FCF | -4.0 | -5.9 | -7.7 | · | · | · | · | |
| EV / Revenue | 1.8 | 5.3 | 6.0 | · | · | · | · | |
| Earnings Yield | -50.4% | -18.7% | -10.2% | 16.2% | · | 6.8% | · |
Estado de resultados 17
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22M | $19M | $18M | $17M | $18M | $19M | $18M | $20M | $15M | $11M | $14M | $14M | $12M | $11M | $9M | $9M | |
| Cost of Revenue | $4M | $4M | $3M | $3M | $3M | $3M | $2M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $2M | |
| Gross Profit | $18M | $16M | $14M | $14M | $15M | $16M | $16M | $16M | $13M | $10M | $12M | $12M | $10M | $9M | $8M | $8M | |
| R&D Expense | $5M | $6M | $6M | $4M | $5M | $6M | $5M | $5M | $5M | $5M | $7M | $4M | $5M | $5M | $3M | $4M | |
| SG&A Expense | $6M | $6M | $7M | $7M | $7M | $6M | $7M | $10M | $8M | $9M | $8M | $6M | $6M | $8M | $5M | $5M | |
| Operating Expenses | $25M | $25M | $25M | $23M | $26M | $28M | $26M | $30M | $29M | $27M | $25M | $21M | $21M | $19M | $15M | $14M | |
| Operating Income | $-7M | $-9M | $-10M | $-9M | $-11M | $-12M | $-10M | $-14M | $-16M | $-17M | $-12M | $-9M | $-11M | $-10M | $-6M | $-6M | |
| Interest Expense | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $10.0K | $7.0K | $4.0K | $-3.0K | $6.0K | |
| Other Non-op | $688.0K | $-395.0K | $20.0K | $-3M | $2M | $-791.0K | $-314.0K | $-1M | $2M | $-66.0K | $6M | $615.0K | $801.0K | $725.0K | · | · | |
| Pretax Income | $-8M | $-11M | $-12M | $-13M | $-10M | $-14M | $-12M | $-16M | $-15M | $-19M | $-7M | $-9M | $-10M | $-9M | $-5M | $-6M | |
| Income Tax | $33.0K | $-11.0K | $-16.0K | $15.0K | $4.0K | $8.0K | $19.0K | $-28.0K | $33.0K | $30.0K | $12.0K | $11.0K | $13.0K | $30.0K | $24.0K | $4.0K | |
| Net Income | $-8M | $-11M | $-12M | $-13M | $-10M | $-14M | $-12M | $-16M | $-15M | $-19M | $-7M | $-9M | $-10M | $-9M | $-5M | $-6M | |
| EPS (Basic) | $-0.25 | $-0.35 | $-0.37 | $-0.46 | $-0.38 | $-0.53 | $-0.44 | $-0.62 | $-0.60 | $-0.73 | $-0.28 | $-0.34 | $-0.41 | $-0.37 | $0.22 | $0.22 | |
| EPS (Diluted) | $-0.25 | $-0.35 | $-0.37 | $-0.46 | $-0.38 | $-0.53 | $-0.44 | $-0.62 | $-0.60 | $-0.73 | $-0.28 | $-0.34 | $-0.41 | $-0.37 | $0.22 | $0.22 | |
| Shares (Basic) | 30,749,894 | 30,540,872 | -53,153,774 | 28,393,445 | 26,367,548 | 26,253,565 | -51,498,934 | 25,983,929 | 25,760,278 | 25,637,783 | -50,512,301 | 25,401,754 | 25,239,723 | 25,202,088 | -49,916,057 | 25,006,995 | |
| Shares (Diluted) | 30,749,894 | 30,540,872 | -53,153,774 | 28,393,445 | 26,367,548 | 26,253,565 | -51,498,934 | 25,983,929 | 25,760,278 | 25,637,783 | -50,512,301 | 25,401,754 | 25,239,723 | 25,202,088 | -49,916,057 | 25,006,995 | |
| EBITDA | $-7M | $-8M | · | $-9M | $-11M | $-11M | · | $-14M | $-16M | $-17M | · | $-9M | $-11M | $-10M | · | $-6M |
Balance general 25
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9M | $8M | $10M | $15M | $12M | $15M | $14M | $19M | $17M | $17M | $22M | $51M | $37M | $28M | $18M | $24M | |
| Short-term Investments | $2M | $6M | $8M | $8M | $3M | $11M | $22M | $26M | $37M | $51M | $67M | $9M | $29M | $45M | $61M | $61M | |
| Receivables | $10M | $10M | $9M | $9M | $11M | $12M | $12M | $10M | $9M | $7M | $8M | $6M | $6M | $5M | $4M | $4M | |
| Inventory | $5M | $6M | $7M | $7M | $8M | $8M | $7M | $6M | $7M | $7M | $6M | $4M | $3M | $3M | $2M | $2M | |
| Prepaid Expense | $2M | $1M | $1M | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $2M | $3M | $2M | $1M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | $8.0K | $135.0K | · | $26.0K | $525.0K | $29.0K | $127.0K | $17.0K | |
| Current Assets | $28M | $32M | $35M | $41M | $36M | $48M | $57M | $64M | $73M | $86M | $104M | $74M | $77M | $83M | $87M | $92M | |
| PP&E (Net) | $8M | $8M | $9M | $10M | $10M | $10M | $10M | $9M | $7M | $4M | $2M | $2M | $2M | $1M | $1M | $1M | |
| Accum. Depreciation | $6M | $6M | $5M | $5M | $4M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Intangibles | $5M | $5M | $6M | $5M | $5M | $5M | $6M | $590.0K | $545.0K | $542.0K | $487.0K | $459.0K | $456.0K | $461.0K | $465.0K | $449.0K | |
| Other Non-current Assets | $593.0K | $534.0K | $612.0K | $1M | $839.0K | $287.0K | $546.0K | $546.0K | $473.0K | $401.0K | $355.0K | $236.0K | $285.0K | $230.0K | $122.0K | $548.0K | |
| Total Assets | $48M | $52M | $56M | $64M | $58M | $70M | $80M | $81M | $88M | $97M | $112M | $81M | $86M | $93M | $98M | $100M | |
| Accounts Payable | $6M | $7M | $9M | $8M | $7M | $9M | $6M | $4M | $4M | $4M | $4M | $3M | $4M | $4M | $3M | $3M | |
| Current Liabilities | $69M | $67M | $63M | $62M | $63M | $23M | $20M | $17M | $14M | $12M | $13M | $12M | $14M | $11M | $11M | $10M | |
| Capital Leases | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $1M | $1M | $306.0K | $405.0K | |
| Total Liabilities | $76M | $75M | $73M | $70M | $71M | $74M | $75M | $69M | $64M | $64M | $62M | $17M | $16M | $14M | $13M | $12M | |
| Long-term Debt | · | · | $43M | $42M | · | · | $42M | · | · | · | · | · | · | · | · | · | |
| Total Debt | $47M | $46M | · | $42M | $42M | $41M | · | $43M | $41M | $41M | · | · | · | · | · | · | |
| Common Stock | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | |
| Paid-in Capital | $400M | $396M | $394M | $393M | $374M | $371M | $368M | $364M | $359M | $353M | $350M | $347M | $344M | $342M | $340M | $338M | |
| Retained Earnings | $-427M | $-419M | $-408M | $-397M | $-384M | $-374M | $-360M | $-348M | $-332M | $-317M | $-298M | $-291M | $-282M | $-272M | $-263M | $-257M | |
| AOCI | $-82.0K | $648.0K | $-1M | $-1M | $-2M | $-413.0K | $-2M | $-2M | $-2M | $-3M | $-2M | $8M | $8M | $8M | $8M | $7M | |
| Stockholders' Equity | $-28M | $-23M | $-17M | $-7M | $-13M | $-5M | $4M | $12M | $24M | $33M | $49M | $63M | $69M | $78M | $85M | $88M | |
| Liabilities + Equity | $48M | $52M | $56M | $64M | $58M | $70M | $80M | $81M | $88M | $97M | $112M | $81M | $86M | $93M | $98M | $100M | |
| Shares Outstanding | 30,926,847 | 30,776,689 | 30,571,662 | 30,493,111 | 26,613,678 | 26,434,658 | 26,354,042 | 26,217,629 | 25,949,906 | 25,789,051 | 25,682,078 | 25,550,694 | 25,447,615 | 25,327,761 | 25,208,436 | 25,030,902 |
Flujo de Efectivo 13
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $605.0K | $627.0K | $700.0K | $574.0K | $552.0K | $521.0K | $409.0K | $310.0K | $204.0K | $203.0K | $187.0K | $164.0K | $146.0K | $135.0K | $130.0K | $138.0K | |
| Stock-based Comp | $2M | $1M | $1M | $3M | $3M | $3M | $3M | $4M | $4M | $3M | $2M | $2M | $1M | $3M | $1M | $1M | |
| Amort. of Intangibles | $196.0K | $204.0K | $160.0K | $153.0K | $152.0K | $135.0K | $36.0K | $23.0K | $17.0K | $17.0K | $9.0K | $9.0K | $8.0K | $9.0K | $8.0K | $8.0K | |
| Other Non-cash | · | $-1M | · | · | · | $335.0K | · | · | · | $-5M | · | · | · | $-3M | · | · | |
| Operating Cash Flow | $-3M | $-10M | $-5M | $-5M | $-10M | $-10M | $-8M | $-7M | $-13M | $-21M | $-11M | $-9M | $-9M | $-9M | $-3M | $-3M | |
| CapEx | $108.0K | $19.0K | $-674.0K | $934.0K | $524.0K | $221.0K | $2M | $4M | $3M | $1M | $296.0K | $502.0K | $299.0K | $284.0K | $70.0K | $104.0K | |
| Investing Cash Flow | $4M | $2M | $11.0K | $-5M | $7M | $11M | $2M | $7M | $12M | $15M | $-57M | $22M | $18M | $19M | $-3M | $-8M | |
| Stock Issued | · | · | $0 | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $437.0K | $6M | $248.0K | $14M | $559.0K | $363.0K | $1M | $1M | $849.0K | $631.0K | $39M | $600.0K | $171.0K | $171.0K | $899.0K | $0 | |
| Net Change in Cash | $830.0K | $-2M | $-5M | $3M | $-3M | $820.0K | $-5M | $1M | $501.0K | $-5M | $-29M | $13M | $9M | $10M | $-6M | $-11M | |
| Taxes Paid | · | · | · | · | · | · | $20.0K | $2.0K | $19.0K | $17.0K | $0 | $0 | $44.0K | $9 | $0 | $0 | |
| Free Cash Flow | · | $-10M | · | · | · | $-11M | · | · | · | $-22M | · | · | · | $-9M | · | · | |
| Levered FCF | · | $-12M | · | · | · | $-12M | · | · | · | $-23M | · | · | · | $-9M | · | · |
Rentabilidad 8
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.9% | 81.7% | · | 81.3% | 81.2% | 84.7% | · | 83.7% | 86.1% | 86.4% | · | 84.5% | 81.2% | 84.2% | · | 83.2% | |
| Operating Margin | -31.6% | -45.7% | · | -53.6% | -60.5% | -63.9% | · | -70.6% | -102.8% | -155.0% | · | -68.2% | -95.0% | -93.9% | · | -63.2% | |
| Net Margin | -35.3% | -55.1% | · | -77.3% | -53.9% | -74.9% | · | -82.9% | -101.3% | -168.0% | · | -63.8% | -88.3% | -87.4% | · | -61.5% | |
| Pretax Margin | -35.2% | -55.2% | · | -77.2% | -53.8% | -74.8% | · | -83.0% | -101.1% | -167.8% | · | -63.8% | -88.2% | -87.1% | · | -61.4% | |
| EBITDA Margin | -31.6% | -42.5% | · | -53.6% | -60.5% | -61.1% | · | -70.6% | -102.8% | -153.1% | · | -68.2% | -95.0% | -92.7% | · | -63.2% | |
| ROA | -14.5% | -17.5% | · | -18.2% | -13.6% | -16.6% | · | -20.0% | -17.7% | -19.6% | · | -9.6% | -11.0% | -9.3% | · | -4.9% | |
| ROE | 37.6% | 76.5% | · | -474.3% | -180.0% | -99.0% | · | -43.1% | -33.3% | -33.9% | · | -11.5% | -12.9% | -10.5% | · | -5.4% | |
| ROIC | -36.6% | -38.3% | · | -25.6% | -38.0% | -32.1% | · | -25.2% | -24.1% | -23.3% | · | -14.8% | -16.3% | -12.8% | · | -6.5% |
Liquidez y Solvencia 5
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.4 | 0.5 | · | 0.7 | 0.6 | 2.1 | · | 3.7 | 5.3 | 7.2 | · | 6.2 | 5.6 | 7.2 | · | 9.6 | |
| Quick Ratio | 0.3 | 0.4 | · | 0.5 | 0.4 | 1.6 | · | 3.2 | 4.6 | 6.3 | · | 5.6 | 5.2 | 6.8 | · | 9.2 | |
| Debt / Equity | -1.7 | -2.0 | · | -6.4 | -3.3 | -9.1 | · | 3.5 | 1.7 | 1.3 | · | · | · | · | · | · | |
| LT Debt / Equity | · | · | · | 0.0 | -3.3 | -9.1 | · | 3.5 | 1.7 | 1.3 | · | · | · | · | · | · | |
| Interest Coverage | -4.7 | -6.2 | · | -7.2 | -8.9 | -9.6 | · | -10.2 | -11.6 | -12.7 | · | -930.6 | -1595.0 | -2477.8 | · | -958.0 |
Eficiencia 3
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.2 | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.6 | 0.5 | · | 0.5 | 0.5 | 0.4 | · | 0.6 | 0.4 | 0.3 | · | 0.7 | 0.9 | 0.7 | · | 0.8 | |
| Receivables Turnover | 2.0 | 1.8 | · | 1.8 | 1.8 | 1.9 | · | 2.4 | 2.1 | 1.9 | · | 2.9 | 2.4 | 2.6 | · | 3.1 |
Valoración (TTM) 14
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $76M | $73M | · | $74M | $72M | $64M | · | $59M | $52M | $47M | · | $45M | $40M | $36M | · | $32M | |
| Net Income TTM | $-41M | $-48M | · | $-53M | $-55M | $-64M | · | $-59M | $-53M | $-47M | · | $-34M | $-31M | $-31M | · | $-27M | |
| Market Cap | $128M | $114M | · | $156M | $141M | $215M | · | $281M | $206M | $413M | · | $373M | $433M | $354M | · | $132M | |
| Enterprise Value | $163M | $146M | · | $175M | $167M | $231M | · | $279M | $192M | $387M | · | · | · | · | · | · | |
| P/E | -2.9 | -2.2 | · | -2.6 | -2.5 | -3.3 | · | -4.7 | -3.8 | -8.7 | · | -16.2 | -54.9 | 29.1 | · | 4.8 | |
| P/S | 1.7 | 1.6 | · | 2.1 | 2.0 | 3.3 | · | 4.7 | 4.0 | 8.8 | · | 8.3 | 10.9 | 10.0 | · | 4.1 | |
| P/B | -4.6 | -4.9 | · | -23.4 | -10.9 | -47.1 | · | 23.0 | 8.6 | 12.7 | · | 5.9 | 6.3 | 4.6 | · | 1.5 | |
| P / Tangible Book | · | · | · | · | · | · | · | 24.2 | 8.8 | 12.9 | · | 6.0 | 6.3 | 4.6 | · | 1.5 | |
| P / Cash Flow | · | -11.3 | · | · | · | -20.9 | · | · | · | -19.8 | · | · | · | -39.0 | · | · | |
| P / FCF | · | -11.3 | · | · | · | -20.4 | · | · | · | -18.8 | · | · | · | -37.8 | · | · | |
| EV / EBITDA | -23.8 | -17.8 | · | -19.1 | -15.0 | -20.4 | · | -20.2 | -12.3 | -22.7 | · | · | · | · | · | · | |
| EV / FCF | · | -14.4 | · | · | · | -21.9 | · | · | · | -17.6 | · | · | · | · | · | · | |
| EV / Revenue | 2.1 | 2.0 | · | 2.4 | 2.3 | 3.6 | · | 4.7 | 3.7 | 8.2 | · | · | · | · | · | · | |
| Earnings Yield | -34.9% | -46.5% | · | -38.9% | -40.3% | -30.5% | · | -21.4% | -26.3% | -11.5% | · | -6.2% | -1.8% | 3.4% | · | 20.7% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $72M | $64M | $50M | $34M | — |
| Margen Bruto % | 82.1% | 85.9% | 84.5% | 82.5% | — |
| Margen Operativo % | -59.4% | -88.1% | -85.1% | -79.9% | — |
| Beneficio neto | $-49M | $-62M | $-35M | $-27M | — |
| EPS Diluido | $-1.74 | $-2.39 | $-1.40 | $1.07 | — |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Deuda / Patrimonio | -2.6 | 9.4 | 0.8 | — | — |
| Ratio corriente | 0.6 | 2.8 | 7.9 | 8.2 | — |
| Ratio Rápido | 0.4 | 2.4 | 7.3 | 7.7 | — |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $-32M | $-58M | $-39M | $-20M | — |
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 81 declarantes · $18.7M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 26 (0 vs trimestre anterior) | 23 (+10 vs trimestre anterior) | 26 (+5 vs trimestre anterior) | 17 (+3 vs trimestre anterior) | -39.7M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $5 509 065 | 1 333 914 | 29,41% | Acciones |
| VANGUARD GROUP INC | $4 326 172 | 1 253 963 | 23,10% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $1 124 496 | 272 127 | 6,00% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $753 320 | 182 402 | 4,02% | Acciones |
| NewEdge Advisors, LLC | $615 085 | 148 931 | 3,28% | Acciones |
| MACQUARIE GROUP LTD | $595 395 | 144 164 | 3,18% | Acciones |
| STATE STREET CORP | $532 675 | 128 977 | 2,84% | Acciones |
| Quantinno Capital Management LP | $434 674 | 105 248 | 2,32% | Acciones |
| Divisadero Street Capital Management, LP | $413 000 | 100 000 | 2,20% | Acciones |
| GOLDMAN SACHS GROUP INC | $316 924 | 76 737 | 1,69% | Acciones |
| NORTHERN TRUST CORP | $284 090 | 68 787 | 1,52% | Acciones |
| Qube Research & Technologies Ltd | $263 428 | 63 784 | 1,41% | Acciones |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $250 881 | 60 746 | 1,34% | Acciones |
| XTX Topco Ltd | $236 075 | 57 161 | 1,26% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $222 847 | 53 958 | 1,19% | Acciones |
| BANK OF AMERICA CORP /DE/ | $213 384 | 51 667 | 1,14% | Acciones |
| MARSHALL WACE, LLP | $203 304 | 49 226 | 1,09% | Acciones |
| Nuveen Asset Management, LLC | $159 002 | 12 422 | 0,85% | Acciones |
| FMR LLC | $134 287 | 32 515 | 0,72% | Acciones |
| IEQ CAPITAL, LLC | $133 812 | 32 400 | 0,71% | Acciones |
| THOMPSON DAVIS & CO., INC. | $128 402 | 31 090 | 0,69% | Acciones |
| Jain Global LLC | $127 101 | 30 775 | 0,68% | Acciones |
| AMERIPRISE FINANCIAL INC | $117 696 | 28 498 | 0,63% | Acciones |
| Russell Investments Group, Ltd. | $115 863 | 28 054 | 0,62% | Acciones |
| IHT Wealth Management, LLC | $101 599 | 24 600 | 0,54% | Acciones |
| Squarepoint Ops LLC | $95 035 | 23 011 | 0,51% | Acciones |
| R Squared Ltd | $94 506 | 22 883 | 0,50% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $92 512 | 22 400 | 0,49% | Opción de compra |
| BlackRock, Inc. | $90 174 | 21 834 | 0,48% | Acciones |
| CITADEL ADVISORS LLC | $87 746 | 21 246 | 0,47% | Acciones |
| Mariner, LLC | $81 090 | 19 634 | 0,43% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $65 254 | 15 800 | 0,35% | Opción de venta |
| CITADEL ADVISORS LLC | $65 254 | 15 800 | 0,35% | Opción de venta |
| Abel Hall, LLC | $65 167 | 15 779 | 0,35% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64 734 | 15 674 | 0,35% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $63 722 | 15 429 | 0,34% | Acciones |
| GABELLI FUNDS LLC | $61 950 | 15 000 | 0,33% | Acciones |
| nVerses Capital, LLC | $56 448 | 13 668 | 0,30% | Acciones |
| China Universal Asset Management Co., Ltd. | $51 625 | 12 500 | 0,28% | Acciones |
| Quadrature Capital Ltd | $48 854 | 11 829 | 0,26% | Acciones |
| MERCER GLOBAL ADVISORS INC /ADV | $48 073 | 11 640 | 0,26% | Acciones |
| Cerity Partners LLC | $41 259 | 9 990 | 0,22% | Acciones |
| Vanguard Global Advisers, LLC | $40 201 | 9 734 | 0,21% | Acciones |
| AlphaQuest LLC | $32 354 | 9 378 | 0,17% | Acciones |
| Arax Advisory Partners | $29 542 | 7 153 | 0,16% | Acciones |
| AQR CAPITAL MANAGEMENT LLC | $28 179 | 6 823 | 0,15% | Acciones |
| RHUMBLINE ADVISERS | $27 302 | 6 611 | 0,15% | Acciones |
| CWM, LLC | $19 632 | 5 306 | 0,10% | Acciones |
| JONES FINANCIAL COMPANIES LLLP | $17 083 | 4 303 | 0,09% | Acciones |
| Tower Research Capital LLC (TRC) | $9 387 | 2 273 | 0,05% | Acciones |
| WELLS FARGO & COMPANY/MN | $9 003 | 2 180 | 0,05% | Acciones |
| Optiver Holding B.V. | $5 856 | 1 418 | 0,03% | Acciones |
| Integrated Wealth Concepts LLC | $5 157 | 1 249 | 0,03% | Acciones |
| PNC Financial Services Group, Inc. | $3 444 | 834 | 0,02% | Acciones |
| OSAIC HOLDINGS, INC. | $2 601 | 630 | 0,01% | Acciones |
| UBS Group AG | $2 172 | 526 | 0,01% | Acciones |
| Allworth Financial LP | $2 070 | 501 | 0,01% | Acciones |
| MORGAN STANLEY | $1 966 | 476 | 0,01% | Acciones |
| Essential Partners LLC | $1 788 | 433 | 0,01% | Acciones |
| IFP Advisors, Inc | $1 689 | 409 | 0,01% | Acciones |
| SBI Securities Co., Ltd. | $1 218 | 295 | 0,01% | Acciones |
| JPMORGAN CHASE & CO | $808 | 190 | 0,00% | Acciones |
| GAMMA Investing LLC | $785 | 190 | 0,00% | Acciones |
| True Wealth Design, LLC | $608 | 147 | 0,00% | Acciones |
| ROTHSCHILD INVESTMENT LLC | $491 | 119 | 0,00% | Acciones |
| NISA INVESTMENT ADVISORS, LLC | $384 | 93 | 0,00% | Acciones |
| Fortitude Family Office, LLC | $285 | 69 | 0,00% | Acciones |
| EverSource Wealth Advisors, LLC | $264 | 64 | 0,00% | Acciones |
| Farther Finance Advisors, LLC | $260 | 62 | 0,00% | Acciones |
| Caitong International Asset Management Co., Ltd | $194 | 47 | 0,00% | Acciones |
| Parallel Advisors, LLC | $165 | 40 | 0,00% | Acciones |
| SJS Investment Consulting Inc. | $141 | 34 | 0,00% | Acciones |
| Virtu Financial LLC | $101 | 24 482 | 0,00% | Acciones |
| Wealth Enhancement Trust Services, Inc. | $99 | 24 | 0,00% | Acciones |
| HRT FINANCIAL LP | $42 | 10 179 | 0,00% | Acciones |
| JPL Wealth Management, LLC | $25 | 6 | 0,00% | Acciones |
| Clearstead Advisors, LLC | $13 | 3 | 0,00% | Acciones |
| Sunbelt Securities, Inc. | $11 | 3 | 0,00% | Acciones |
| BARCLAYS PLC | $4 | 1 | 0,00% | Acciones |
| Capital Analysts, LLC | $3 | 652 | 0,00% | Acciones |
| ROYAL BANK OF CANADA | $0 | 56 | 0,00% | Acciones |
Informantes de la empresa 20 insiders · 11 directivos · 11 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Cary Guy Vance | President and CEO | 29 de mayo de 2026 A | 40 771 | 0 | 0 | $0 |
| James Corbett | CEO | 21 de enero de 2025 A | 11 580 | 0 | 0 | $0 |
| David D O'Toole | CFO | 12 de junio de 2026 A | 152 927 | 5 | 0 | $47 094 |
| Sean Ekins | Interim CFO | 6 de junio de 2023 A | 5 000 | 0 | 0 | $0 |
| Michael Holder | Chief Financial Officer | 1 de julio de 2022 A | 46 450 | 0 | 0 | $0 |
| David Mcintyre | Chief Financial Officer | 17 de julio de 2020 P | 893 | 0 | 0 | $0 |
| Kathy M. Mcgee | Chief Operating Officer | 1 de julio de 2022 A | 46 450 | 0 | 0 | $0 |
| Nicole Kelsey | Chief Legal Officer | 18 de febrero de 2026 A | 98 390 | 0 | 0 | $0 |
| Donna Shiroma | General Counsel | 31 de mayo de 2024 A | 45 951 | 0 | 0 | $0 |
| Andrew Quick | Chief Technology Officer | 6 de junio de 2023 A | 46 450 | 0 | 0 | $0 |
| Erin Liberto | Chief Commercial Officer | 1 de julio de 2022 A | 46 450 | 0 | 0 | $0 |
| Joseph Fralin Woody | Consejero | 9 de junio de 2026 P | 107 961 | 5 | 0 | $104 900 |
| Suzanne Crowe | Consejero | 3 de junio de 2026 A | 69 148 | 0 | 0 | $0 |
| Michael E Tarnoff | Consejero | 3 de junio de 2026 A | 48 464 | 0 | 0 | $0 |
| Robert Mcnamara | Consejero | 20 de enero de 2026 A | 108 985 | 2 | 0 | $95 000 |
| Jeremy Curnock Cook | Consejero | 20 de enero de 2026 A | 62 050 | 0 | 0 | $0 |
| Jan Stern Reed | Consejero | 20 de enero de 2026 A | 73 225 | 0 | 0 | $0 |
| Lou Panaccio | Consejero | 21 de enero de 2025 A | 56 428 | 0 | 0 | $0 |
| Michael S Perry | Consejero | 21 de noviembre de 2022 M | 229 543 | 0 | 0 | $0 |
| Louis Drapeau | Consejero | 22 de diciembre de 2021 A | 4 689 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 10 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| IWC · iShares Trust | 0,03% | 108 036 SH | 8 de agosto de 2026 | Diario |
| GSSC · Goldman Sachs ETF Trust | 0,01% | 18 465 NS | 31 de mayo de 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 3 453 NS | 31 de mayo de 2026 | N-PORT |
| RSSL · Global X Funds | 0,00% | 5 475 NS | 30 de abril de 2026 | N-PORT |
| ITWO · ProShares Trust | 0,00% | 663 NS | 31 de mayo de 2026 | N-PORT |
| UWM · ProShares Trust | 0,00% | 517 NS | 31 de mayo de 2026 | N-PORT |
| URTY · ProShares Trust | 0,00% | 521 NS | 31 de mayo de 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 13 NS | 31 de mayo de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 341 039 SH | 8 de agosto de 2026 | Diario |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 958 401 SH | 8 de agosto de 2026 | Diario |